SCYNEXIS Inc (SCYX) Stock Analysis

Verdict: BUY

Up to $214M non-dilutive BARDA funding de-risks SCY-247 development, but clinical execution and FDA trial hurdles remain key swing factors.

Investment score: 66/100

Analysis as of

Is SCYNEXIS Inc stock worth reviewing? The TradeMates thesis

SCYNEXIS represents a high-upside micro-cap biotech whose primary funding overhang has been neutralized by an up to $214M BARDA award, providing ample runway for clinical development at a deeply discounted price-to-book valuation.

7-factor investment score

SCYNEXIS Inc opportunities and risks

What speaks for SCYX

What speaks against SCYX

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
SCYXn/a1.7xn/a100.0%-53.3%-41.3%
TLPHn/a58646.5xn/a100.0%-1507600.0%-20.9%
HYPDn/a40.4xn/a78.4%474.9%-94.6%
PLTH.CNn/a0.4xn/a41.0%-66.9%-26.8%
ODTC3227.6x0.0x846.2x0.0%0.0%0.1%
IMAn/a0.0x0.8x0.0%0.0%-111.3%
Peer mediann/a0.4xn/a41.0%0.0%-26.8%

Frequently asked questions about SCYNEXIS Inc (SCYX)

Is SCYX stock a good investment?

The TradeMates model rates SCYNEXIS Inc as BUY with an investment score of 66/100. SCYNEXIS represents a high-upside micro-cap biotech whose primary funding overhang has been neutralized by an up to $214M BARDA award, providing ample runway for clinical development at a deeply discounted price-to-book valuation. This is algorithmic model output, not personal investment advice.

Is SCYX stock a buy?

The TradeMates model verdict for SCYX is BUY with an investment score of 66/100. Treat this as a model signal to review, not a personal buy recommendation.